Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition
Translational Cancer Research · 2024-01 · 13 (1) · 348-362
DOI: 10.21037/tcr-23-1317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Cancer Research, 2024-01. Verfasst von Shengqian Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Although there are many treatments for breast cancer, such as surgery, radiotherapy, chemotherapy, estrogen receptor antagonists, immune checkpoint inhibitors and so on. However, safer and more effective therapeutic drugs for breast cancer are needed. Sinensetin, a safer therapeutic drugs, come from citrus species and medicinal plants used in traditional medicine, while its role and underlying mechanism in breast cancer remain unclear. Our study aimed to investigate the role and mechanism of sinensetin in breast cancer.
Methods
Cell Counting Kit-8 (CCK-8) was used to determine the safe concentration of sinensetin in MCF-10A, MCF7 and MDA-MB-231 cells; 120 μM sinensetin was used in subsequent experiments. Real time polymerase chain reaction (RT-PCR), Western blotting, Terminal Deoxynucleotidyl Transferase mediated dUTP Nick-End Labeling (TUNEL) apoptosis assay, Transwell invasion assay and Clone formation assay were used in this study to determine cell viability, mRNA expression, protein levels, apoptosis, proliferation, invasion and so on.
Results
Herein, our results showed that 120 μM sinensetin suppressed the cell viability and promoted apoptosis of MCF7 and MDA-MB-231 cells. Treatment with 120 µM sinensetin for 24 h showed no significant toxicity to normal mammary cells; 120 μM sinensetin decreased cell proliferation, invasion, and epithelial-mesenchymal transition (EMT), and downregulated β-catenin, lymphatic enhancing factor 1 (LEF1), T-cell factor (TCF) 1/TCF7, and TCF3/TCF7L1 expression in MCF7 and MDA-MB-231 cells. The Wnt agonist SKL2001 reversed the inhibitory effect of sinensetin on cell survival, metastasis, and EMT. Sinensetin-induced downregulation of β-catenin, LEF1, and TCF1/TCF7 expression were upregulated by SKL2001 in MCF7 and MDA-MB-231 cells.
Conclusions
In summary, sinensetin suppressed the metastasis of breast cancer cell via inhibition of Wnt/β-catenin pathway and there were no adverse effects on normal breast cells. Our study confirmed the role of sinensetin in breast cancer cells and provided a better understanding of the underlying mechanism.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
- Department of Hepatobiliary Surgery, Ningbo First Hospital, Ningbo, China.
- Department of Plastic and Reconstructive Surgery, The Third Hospital of Ninghai County, Ningbo, China.
Zitieren
APA
Zhu, S., Meng, L., Wei, P., Gu, G., & Duan, K. (2024). Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition. Translational Cancer Research, 13(1), 348-362. https://doi.org/10.21037/tcr-23-1317
Vancouver
Zhu S, Meng L, Wei P, Gu G, Duan K. Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition. Translational Cancer Research. 2024;13(1):348-362. doi:10.21037/tcr-23-1317
BibTeX
@article{Zhu2024,
author = {Zhu, Shengqian and Meng, Lifei and Wei, Peng and Gu, Guowen and Duan, Keli},
title = {Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition},
journal = {Translational Cancer Research},
year = {2024},
volume = {13},
number = {1},
pages = {348--362},
doi = {10.21037/tcr-23-1317}
}
EUVIMED